Amneal Pharmaceuticals, Inc. (AMRX) Balance Sheet
AMRX balance sheet, 2025
December 31, 2025 · U.S. dollars$3.68B assets = $3.67B liabilities + $6.0M equity
Both columns are drawn to the same scale: what AMRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
AMRX financial health
Descriptive bands, not a rating. Fiscal 2025.
AMRX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.22B2016 | $3.68B2025 | +13.1%/yr | |
| Total liabilities | $1.39B2016 | $3.67B2025 | +11.4%/yr | |
| Shareholders’ equity | −$185.3M2016 | −$70.8M2025 | — | |
| Cash & short-term investments | $31.7M2016 | $310.9M2025 | +28.9%/yr | |
| Total debt | $1.20B2016 | $2.74B2025 | +9.6%/yr | |
| Net cash (debt) | −$1.17B2016 | −$2.43B2025 | −$1.3B | |
| Working capital | $501.0M2016 | $1.03B2025 | +$528.5M | |
| Book value per share | −$0.982016 | −$0.222025 | — | |
| Current ratio | 3.232016 | 2.172025 | −1.06 | |
| Debt / equity | 3.002018 | 139.052023 | +136.05 | |
| Shares outstanding | 189.0M2016 | 324.8M2025 | +6.2%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AMRX assets
AMRX liabilities and equity
AMRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
AMRX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $310.9M | $112.4M | $93.7M | $27.8M | $247.8M | $343.1M | $152.3M | $213.4M | $74.2M | $31.7M |
| Cash & equivalents | $310.9M | $110.6M | $91.5M | $26.0M | $247.8M | $341.4M | $151.2M | $213.4M | $74.2M | $27.4M |
| Short-term investments | — | $1.9M | $2.2M | $1.8M | $1.2M | $1.7M | $1.1M | $2.1M | $1.9M | $4.4M |
| Receivables | $939.9M | $775.7M | $645.7M | $741.8M | $694.7M | $639.0M | $604.4M | $565.3M | $351.4M | $394.8M |
| Inventory | $606.3M | $612.5M | $581.4M | $530.7M | $489.4M | $490.6M | $381.1M | $457.2M | $284.0M | $266.2M |
| Other current assets | $54.1M | $87.2M | $57.1M | $111.5M | $88.2M | $78.8M | $72.4M | $50.7M | $62.4M | $33.4M |
| Total current assets | $1.91B | $1.59B | $1.38B | $1.41B | $1.52B | $1.55B | $1.21B | $1.29B | $771.9M | $726.1M |
| Property, plant & equipment (net) | $550.3M | $523.7M | $550.1M | $589.4M | $639.0M | $604.7M | $620.6M | $544.1M | $486.8M | $407.4M |
| Goodwill & intangible assets | $1.16B | $1.33B | $1.49B | $1.69B | $1.76B | $1.83B | $1.80B | $2.08B | $71.0M | $74.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $16.4M | $0 | $0 | $0 |
| Other non-current assets | $57.8M | $60.1M | $55.5M | $103.2M | $20.6M | $22.3M | $16.5M | $440.8M | $12.2M | $10.9M |
| Total assets | $3.68B | $3.50B | $3.47B | $3.80B | $3.94B | $4.01B | $3.67B | $4.35B | $1.34B | $1.22B |
| Liabilities | ||||||||||
| Accounts payable | $254.7M | $259.8M | $143.6M | $166.8M | $131.1M | $154.1M | $103.0M | $114.8M | $70.0M | $60.0M |
| Short-term debt | $21.6M | $340.3M | $227.6M | $104.6M | $46.0M | $57.5M | $37.0M | $21.7M | $89.5M | $37.0M |
| Deferred revenue | — | — | $398.4M | — | — | — | — | $17.4M | $137.1M | — |
| Total current liabilities | $881.6M | $1.13B | $846.6M | $752.8M | $677.2M | $676.9M | $550.4M | $553.9M | $296.9M | $225.1M |
| Long-term debt | $2.57B | $2.16B | $2.43B | $2.59B | $2.68B | $2.74B | $2.67B | $2.67B | $769.5M | $813.5M |
| Lease obligations | $117.2M | $107.1M | $109.9M | $123.5M | $127.4M | $123.9M | $135.5M | $39.3M | $40.3M | — |
| Other long-term liabilities | $225.6M | $254.4M | $137.2M | $245.6M | $215.4M | $237.1M | $94.2M | $232.8M | $651.1M | $346.0M |
| Total liabilities | $3.67B | $3.55B | $3.41B | $3.59B | $3.57B | $3.65B | $3.32B | $3.46B | $1.72B | $1.39B |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $3.1M | $3.1M | $3.1M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M | $2.7M | $2.7M |
| Retained earnings (deficit) | −$535.0M | −$607.1M | −$490.2M | −$406.2M | −$276.2M | −$286.8M | −$377.9M | −$20.9M | −$382.8M | −$175.2M |
| Treasury stock | — | — | — | — | — | — | — | — | −$2.2M | −$2.2M |
| Accumulated other comprehensive income | −$110.7M | −$65.5M | −$32.3M | $9.9M | −$24.8M | −$41.3M | −$68,000 | −$7.8M | −$14.2M | — |
| Minority interest | −$535,000 | −$245,000 | $230,000 | −$114.4M | $6.6M | $41.7M | $114.8M | $391.6M | $0 | — |
| Total shareholders' equity | −$70.8M | −$109.3M | $19.8M | $298.4M | $360.3M | $303.3M | $232.0M | $896.4M | −$385.7M | −$185.3M |
| Key figures | ||||||||||
| Total debt | $2.74B | $2.59B | $2.75B | $2.85B | $2.88B | $3.00B | $2.77B | $2.69B | $1.48B | $1.20B |
| Net cash (debt) | −$2.43B | −$2.48B | −$2.66B | −$2.82B | −$2.63B | −$2.66B | −$2.62B | −$2.48B | −$1.41B | −$1.17B |
| Working capital | $1.03B | $458.0M | $531.3M | $659.0M | $842.9M | $874.6M | $659.8M | $732.8M | $475.1M | $501.0M |
| Tangible book value | −$1.23B | −$1.44B | −$1.47B | −$1.40B | −$1.40B | −$1.52B | −$1.57B | −$1.18B | −$456.8M | −$259.7M |
| Book value per share | −$0.22 | −$0.35 | $0.11 | $1.98 | $2.37 | $2.04 | $1.76 | $7.04 | −$3.36 | −$0.98 |
| Shares outstanding | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M | 148.9M | 132.1M | 127.3M | 114.9M | 189.0M |
| Current ratio | 2.17 | 1.41 | 1.63 | 1.88 | 2.24 | 2.29 | 2.20 | 2.32 | 2.60 | 3.23 |
| Quick ratio | 1.42 | 0.79 | 0.87 | 1.02 | 1.39 | 1.45 | 1.37 | 1.41 | 1.43 | 1.89 |
| Debt / equity | — | — | 139.05 | 9.53 | 7.98 | 9.89 | 11.94 | 3.00 | — | — |
| Equity / assets | −1.9% | −3.1% | 0.6% | 7.9% | 9.1% | 7.6% | 6.3% | 20.6% | −28.7% | −15.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $127.6M | $197.7M | $310.9M | $201.2M | $81.2M | $59.2M | $112.4M | $74.0M | $47.2M | $48.5M | $93.7M | $92.1M |
| Cash & equivalents | $127.6M | $197.7M | $310.9M | $201.2M | $81.2M | $59.2M | $110.6M | $74.0M | $43.8M | $48.5M | $91.5M | $86.9M |
| Short-term investments | — | — | — | — | — | — | $1.9M | — | $3.4M | — | $2.2M | $5.1M |
| Receivables | $1.02B | $902.7M | $939.9M | $924.1M | $849.3M | $800.3M | $775.7M | $786.2M | $803.4M | $704.1M | $645.7M | $690.9M |
| Inventory | $678.0M | $641.6M | $606.3M | $614.5M | $609.0M | $601.4M | $612.5M | $596.4M | $575.6M | $570.7M | $581.4M | $576.5M |
| Other current assets | $120.7M | $56.0M | $54.1M | $98.6M | $45.3M | $49.5M | $87.2M | $56.7M | $59.3M | $56.9M | $57.1M | $96.6M |
| Total current assets | $1.95B | $1.80B | $1.91B | $1.84B | $1.58B | $1.51B | $1.59B | $1.51B | $1.49B | $1.38B | $1.38B | $1.46B |
| Property, plant & equipment (net) | $567.3M | $558.8M | $550.3M | $538.1M | $546.3M | $522.7M | $523.7M | $532.9M | $528.9M | $544.8M | $550.1M | $560.8M |
| Goodwill & intangible assets | $1.18B | $1.13B | $1.16B | $1.18B | $1.25B | $1.29B | $1.33B | $1.38B | $1.42B | $1.46B | $1.49B | $1.58B |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $80.7M | $54.9M | $57.8M | $39.5M | $44.8M | $45.4M | $60.1M | $36.3M | $77.0M | $73.7M | $55.5M | $89.0M |
| Total assets | $3.78B | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B | $3.50B | $3.46B | $3.51B | $3.46B | $3.47B | $3.69B |
| Liabilities | ||||||||||||
| Accounts payable | $244.2M | $227.7M | $254.7M | $266.4M | $666.8M | $192.5M | $259.8M | $235.0M | $199.6M | $175.3M | $143.6M | $177.4M |
| Short-term debt | $121.4M | $21.5M | $21.6M | $21.5M | $335.4M | $337.5M | $340.3M | $381.0M | $451.6M | $228.7M | $227.6M | $122.5M |
| Deferred revenue | — | — | — | — | — | — | — | — | $432.4M | $400.3M | $398.4M | $3.5M |
| Total current liabilities | $883.2M | $728.0M | $881.6M | $862.1M | $1.11B | $1.08B | $1.13B | $1.10B | $1.11B | $834.4M | $846.6M | $760.6M |
| Long-term debt | $2.56B | $2.57B | $2.57B | $2.57B | $2.15B | $2.15B | $2.16B | $2.17B | $2.18B | $2.42B | $2.43B | $2.58B |
| Lease obligations | $121.5M | $124.7M | $117.2M | $112.0M | $114.3M | $103.7M | $107.1M | $110.4M | $112.0M | $113.6M | $109.9M | $115.3M |
| Other long-term liabilities | $211.8M | $292.6M | $225.6M | $281.2M | $216.0M | $194.8M | $254.4M | $229.8M | $222.1M | $219.0M | $137.2M | $152.3M |
| Total liabilities | $3.66B | $3.59B | $3.67B | $3.71B | $3.47B | $3.42B | $3.55B | $3.49B | $3.51B | $3.47B | $3.41B | $3.50B |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $3.2M | $3.2M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M | $3.1M |
| Retained earnings (deficit) | −$415.1M | −$472.7M | −$535.0M | −$570.1M | −$572.5M | −$594.9M | −$607.1M | −$576.0M | −$575.8M | −$581.8M | −$490.2M | −$391.5M |
| Accumulated other comprehensive income | −$100.7M | −$112.2M | −$110.7M | −$105.9M | −$97.4M | −$85.7M | −$65.5M | −$73.8M | −$30.4M | −$23.7M | −$32.3M | $3.9M |
| Minority interest | $0 | −$558,000 | −$535,000 | −$497,000 | −$415,000 | — | — | — | — | — | — | — |
| Total shareholders' equity | $33.0M | −$45.4M | −$70.8M | −$109.5M | −$112.5M | −$131.7M | −$109.3M | −$93.4M | −$57.5M | −$63.7M | $19.8M | $330.9M |
| Key figures | ||||||||||||
| Total debt | $2.79B | $2.70B | $2.74B | $2.69B | $2.58B | $2.58B | $2.59B | $2.64B | $2.73B | $2.75B | $2.75B | $2.80B |
| Net cash (debt) | −$2.66B | −$2.50B | −$2.43B | −$2.48B | −$2.50B | −$2.52B | −$2.48B | −$2.57B | −$2.68B | −$2.70B | −$2.66B | −$2.71B |
| Working capital | $1.06B | $1.07B | $1.03B | $976.4M | $477.6M | $434.6M | $458.0M | $418.1M | $371.1M | $545.7M | $531.3M | $695.5M |
| Tangible book value | −$1.15B | −$1.17B | −$1.23B | −$1.29B | −$1.36B | −$1.42B | −$1.44B | −$1.47B | −$1.48B | −$1.52B | −$1.47B | −$1.25B |
| Book value per share | $0.10 | −$0.14 | −$0.22 | −$0.34 | −$0.35 | −$0.41 | −$0.35 | −$0.30 | −$0.18 | −$0.21 | $0.08 | $2.07 |
| Shares outstanding | 328.1M | 328.9M | 324.8M | 324.8M | 322.4M | 324.0M | 309.9M | 309.6M | 319.0M | 307.3M | 243.7M | 159.7M |
| Current ratio | 2.20 | 2.47 | 2.17 | 2.13 | 1.43 | 1.40 | 1.41 | 1.38 | 1.33 | 1.65 | 1.63 | 1.91 |
| Quick ratio | 1.30 | 1.51 | 1.42 | 1.31 | 0.84 | 0.80 | 0.79 | 0.79 | 0.76 | 0.90 | 0.87 | 1.03 |
| Debt / equity | 84.54 | — | — | — | — | — | — | — | — | — | 139.05 | 8.48 |
| Equity / assets | 0.9% | −1.3% | −1.9% | −3.0% | −3.3% | −3.9% | −3.1% | −2.7% | −1.6% | −1.8% | 0.6% | 9.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 27, 2026); data from EODHD.
AMRX financial position
At the end of fiscal 2025 (December 31, 2025), Amneal Pharmaceuticals had total assets of $3.7 billion (up 5.1% from a year earlier), total liabilities of $3.7 billion and shareholders' equity of -$70.8 million. It held $310.9 million in cash and short-term investments against $2.7 billion of debt, net debt of $2.4 billion. Its current ratio was 2.17. In the latest quarter (ended June 30, 2026) total assets were $3.8 billion and equity $33.0 million.
Related: AMRX income statement, AMRX cash flow statement, AMRX key metrics. See the AMRX stock overview for the latest quote and news.
AMRX balance sheet FAQ
What are Amneal Pharmaceuticals's total assets?
Amneal Pharmaceuticals reported total assets of $3.7 billion at the end of fiscal 2025 (December 31, 2025), compared with $3.5 billion a year earlier.
How much debt does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals had $2.7 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals held $310.9 million in cash and short-term investments at the end of fiscal 2025; with $2.7 billion of debt that is net debt of $2.4 billion.
What is Amneal Pharmaceuticals's book value?
Amneal Pharmaceuticals's shareholders' equity (book value) was -$70.8 million at the end of fiscal 2025, or −$0.22 per share.
What is Amneal Pharmaceuticals's current ratio?
Amneal Pharmaceuticals had current assets of $1.9 billion and current liabilities of $881.6 million, a current ratio of 2.17 (it can cover its short-term obligations).
How much goodwill does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals carried $1.2 billion of goodwill and intangible assets, 31.5% of total assets, at the end of fiscal 2025.